Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score

Purpose Peginterferon (PEG-IFN) and ribavirin (RBV) combination treatment for patients with chronic hepatitis C (CHC), infected by genotype-1 hepatitis C virus with high viral loads, results in a sustained viral response (SVR) in ~50%. However, a trend of decreasing SVR in the older patients has bee...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology international 2012-10, Vol.6 (4), p.744-752
Main Authors: Ebinuma, Hirotoshi, Saito, Hidetsugu, Tada, Shinichiro, Nakamoto, Nobuhiro, Ohishi, Tazuko, Tsunematsu, Satoshi, Kumagai, Naoki, Tsuchimoto, Kanji, Tsukada, Nobuhiro, Inagaki, Yasutaka, Horie, Yoshinori, Takahashi, Masahiko, Atsukawa, Kazuhiro, Okamura, Yukishige, Kanai, Takanori, Hibi, Toshifumi
Format: Article
Language:English
Subjects:
Age
Body weight
Colorectal Surgery
Erythrocytes
Genotypes
Hemoglobin
Hepatitis C
Hepatitis C virus
Hepatology
Medicine
Medicine & Public Health
Original Article
Platelets
Ribavirin
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Peginterferon (PEG-IFN) and ribavirin (RBV) combination treatment for patients with chronic hepatitis C (CHC), infected by genotype-1 hepatitis C virus with high viral loads, results in a sustained viral response (SVR) in ~50%. However, a trend of decreasing SVR in the older patients has been reported. In the present study, we verified this trend of treatment efficacy in older patients using the propensity score (PS). Methods We conducted a survey of 327 patients with CHC (genotype 1 and high viral loads) who were treated with PEG-IFN and RBV for 48 weeks. The SVR rate was compared between patients =60 and
ISSN:1936-0533
1936-0541
DOI:10.1007/s12072-011-9312-9